Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination

Clinical Drug Investigation

Volumn 32, Issue 10, 2012, Pages 649-664

  Volpe, Massimo ^a,b   Christian Rump, Lars ^c   Ammentorp, Bettina ^d   Laeis, Petra ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d DAIICHI SANKYO CO   (Japan)

Author keywords

amlodipine; Antihypertensives; fixed dose combination therapy; hydrochlorothiazide; olmesartan medoxomil; triple combination therapy.

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; OLMESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; AGING; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES; YOUNG ADULT;

EID: 84865487190     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11636320-000000000-00000     Document Type: Article

References (35)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-87 (Pubitemid 46924065)
2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121-58
3. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11,000 participants from 42 trials. Am J Med 2009; 122 (3): 290-300
4. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417-28
5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
6. Sowers JR, Raij L, Jialal I, et al. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens 2010; 28 (8): 1761-9
7. Chrysant S, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30 (4): 587-604 (Pubitemid 351680489)
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805-16 (Pubitemid 37509488)
9. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallelgroup study. Clin Ther 2010; 32 (7): 1252-69
10. Lloyd-Jones DM, Evans JC, Larson MG, et al. Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002; 40 (5): 640-6 (Pubitemid 35278599)
11. Weycker D, Edelsberg J, Vincze G, et al. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother 2008; 42 (2): 169-76 (Pubitemid 351238563)
12. Volpe M, Miele C, Haag U. Efficacy and safety of a steppedcare regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009; 29 (6): 381-91
13. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009; 11 (9): 475-82
14. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009; 54 (1): 32-9
15. Volpe M, Tocci G. Redefining blood pressure targets in high-risk patients? lessons from coronary endpoints in recent randomized clinical trials. Am J Hypertens 2011; 24 (10): 1060-8
16. Tocci G, Volpe M. Modern clinical management of arterial hypertension: fixed or free combination therapies? High Blood Press Cardiovasc Prev 2011; 18 Suppl. 1: 3-11
17. Tocci G, Volpe M. Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy. Expert Rev Cardiovasc Ther 2011; 9 (7): 829-40
18. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55 (2): 399-407
19. World Health Organization. Reducing risks, promoting healthy life. The World Health Report 2002 [online]. Available from URL: http://www.who.int/whr/ 2002/en/whr02-en.pdf [Accessed 2008 Sep 17]
20. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am JHypertens 2004; 17 (3): 252-9 (Pubitemid 38293331)
21. Volpe M, Brommer P, Haag U, et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009; 29 (1): 11-25
22. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich) 2008; 10 (12): 911-21
23. Rump LC, Girerd X, Sellin L, et al. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens 2010; 25 (9): 565-74
24. Fogari R, Taddei S, Holm-Bentzen M, et al. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin Drug Investig 2010; 30 (9): 581-97
25. Chrysant SG, Lee J, Melino M, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 2010; 24 (11): 730-8
26. Chrysant SG, Chavanu KJ, Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs 2009; 9 (4): 241-51
27. Mourad JJ, Le Jeune S. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009; 29 (6): 419-25
28. Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis 2010; 4 (4): 209-21
29. Oparil S, Lee J, Karki S, et al. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol 2009; 54 (5): 427-36
30. Ram CV, Sachson R, Littlejohn T, et al. Management of hypertension inpatients with diabetes usingan amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Am J Cardiol 2011; 107 (9): 1346-52
31. Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/-hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13 (6): 404-12
32. Neutel JM, Kereiakes DJ, BENIFICIARY Investigators. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am J Cardiovasc Drugs 2010; 10 (5): 289-303
33. Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin 2010; 26 (3): 721-8
34. Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich) 2009; 11 (8): 411-21
35. Oparil S, Chrysant SG, Melino M, et al. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens 2010; 24 (12): 831-8